A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer.

Trial Profile

A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Alliance
  • Most Recent Events

    • 01 May 2017 Results (n=48) assessing genomic characterization of HER positive breast cancer patients and its predictive role for treatment efficacy with chemotherapy and trastuzumab using patient data from NCT00513292 and NCT00353483 trials, published in the Annals of Oncology
    • 12 Nov 2013 Primary endpoint 'Complete-pathological-response-rate' has not been met.
    • 12 Nov 2013 Results published in the Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top